RESEARCH ARTICLE

GIMAP5 Deficiency Is Associated with Increased AKT Activity in T Lymphocytes

Xi-Lin Chen¹, Daniel Serrano¹, Marian Mayhue¹, Kasper Hoebe², Subburaj Illoganumaran¹,³, Sheela Ramanathan¹,³*

¹ Immunology Division, Department of Pediatrics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, J1H 5N4, Québec, Canada, ² Department of Pediatrics, Division of Cellular and Molecular Immunology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, United States of America, ³ Centre de Recherche Clinique, Université de Sherbrooke, Sherbrooke, J1H 5N4, Québec, Canada

* Sheela.Ramanathan@Usherbrooke.ca

Abstract

Long-term survival of T lymphocytes in quiescent state is essential to maintain their cell numbers in secondary lymphoid organs. In mice and in rats, the loss of functional GTPase of the immune associated nucleotide binding protein 5 (GIMAP5) causes peripheral T lymphopenia due to spontaneous death of T cells. The underlying mechanism responsible for the disruption of quiescence in Gimap5 deficient T cells remains largely unknown. In this study, we show that loss of functional Gimap5 results in increased basal activation of mammalian target of rapamycin (mTOR), independent of protein phosphatase 2A (PP2A) or AMP-activated protein kinase (AMPK). Our results suggest that the constitutive activation of the phosphoinositide 3-kinase (PI3K) pathway may be one of the consequences of the absence of functional GIMAP5.

Introduction

The GTPase of immune-associated protein (Gimap) family is predominantly expressed in lymphocytes and cells of the hematopoietic system [1,2]. In diabetes prone Bio-Breeding (BB-DP) rats, the lyp allele arises from a frame-shift mutation within the Gimap5 gene that deletes 223 amino acids at the C-terminus [3,4]. The life span of T cells is reduced in the periphery of Gimap5²/² rats resulting in a profound T lymphopenia in the secondary lymphoid organs [5–7]. Two independently generated lines of Gimap5 deficient mice also exhibit progressive loss of T cell populations [8,9]. Whereas the cell survival defect is confined to T cells in Gimap5²/² rats, mice lacking Gimap5 show defects in various hematopoietic cell types including a breakdown of quiescence in hematopoietic stem cells [8–10]. Despite a decade of efforts by several groups, mechanisms underlying the pro-survival function of GIMAP5 remain unclear.

Different pathways that contribute to the maintenance of quiescence dictate the lifespan of naïve T cells in the periphery. Basal homeostatic signals through the T cell receptor (TCR) and interleukin-7 receptor (IL-7R) are required to maintain the survival of post-thymic naïve T
AMPK, AMP-activated protein kinase; PI3K, phosphoinositide 3-kinase; BB-DP, diabetes prone Bio Breeding; TCR, T cell receptor; IL-7R, interleukin-7 receptor; JAK/STAT, Janus kinase/signal transducers and activators of transcription; LKB1, liver kinase B1; mTORC1, mTOR complex 1; S6K, S6 kinase; TSC1/2, tuberous sclerosis complex; RHEB, RAS homologue enriched in brain; eIF-4F, eukaryotic initiation factor 4E; 4EBP1, eIF-4E binding protein 1; Ca²⁺, calcium; FOXO, suppression of eukaryotic initiation factor 4E; RAPTOR, regulatory associated protein of mTOR.

**Materials and Methods**

**Animals**

*Gimap5phosphosphinidyhydrazonesph/sph* mice [9] were crossed with OT-II TCR transgenic mice to generate OTII *Gimap5phosphosphinidyhydrazonesph/sph* mice. As *Gimap5phosphosphinidyhydrazonesph/sph* mice do not survive beyond 3–4 months, female *Gimap5phosphosphinidyhydrazonesph/+* mice were crossed with male *Gimap5phosphosphinidyhydrazonesph/+* mice. C57Bl/6 mice were purchased from Charles River Canada. *Gimap5phosphosphinidyhydrazonesph/+* and *Gimap5phosphosphinidyhydrazonesph/sph* rats in the ACI.1u background have been described before [35]. Mice and rats were bred and maintained under specific pathogen free conditions at the Université de Sherbrooke. The institutional animal ethics committee approved all the protocols (protocol number 050-13B).
Reagents
LY294002 (LY), oligomycin, fluoro-carbonyl cyanide phenylhydrazone (FCCP), rotenone, antimycin A, RPMI–1640 cell culture medium, fetal bovine serum (FBS) and antibody against actin were from Sigma Aldrich. Thapsigargin (TG), rapamycin, okadaic acid (OA), CAL–101 and calyculin A were from Calbiochem. OVA323-339 peptide (ISQAVHAAHAEINEAGR) was custom synthesized by Genscript (New Jersey, USA). ATP detection kit, Dynabeads CD4 T cell kit for negative selection and dynabeads pan mouse IgG were from Life Technologies. Anti-mouse CD3 (2C11), anti-mouse CD28 (37.51), anti-rat TCR (R73) and anti-Rat CD28 (IJ319) were obtained from BD Pharmingen Biosciences. Goat anti-hamster and goat anti-mouse antibodies for cross-linking were purchased from Jackson ImmunoResearch Laboratories. PP2A immuno-precipitation phosphatase assay kit was from Upstate/Millipore. Enhanced chemiluminescence (ECL) was obtained from GE Healthcare. Antibodies to phosphorylated and total AMPK\(\alpha\) (Thr172), AMPK\(\beta\)1 (Ser108), Acetyl CoA carboxylase (ACC) (Ser79), S6(S235/236), 4EBP1(Thr37/46), AKT(S473) and FOXO1(T24) were obtained from Cell Signaling Technology.

T cell preparation and stimulation
CD4\(^+\) T cells were used for all the experiments as the paucity of CD8\(^+\) T cells in Gimap5 mutant rats and mice precludes their isolation in sufficient numbers to carry out any experiment. Single-cell suspension from pooled lymph nodes (inguinal, axillary, brachial, mesenteric and cervical) of mice or rats were suspended in PBS supplemented with 2% FCS. CD4\(^+\) T cells were purified by negative selection using magnetic beads following manufacturer’s instructions (Dynabeads, Life Technologies). T cells were stimulated by crosslinking with the anti-CD3 and or anti-CD28 mAb as required. Goat anti-hamster or anti-mouse antibodies were used as cross-linking agents for T cells from mice and rats, respectively. OT-II CD4\(^+\) T cells were stimulated with OVA323-339 peptide (0.5\(\mu\)M) presented by irradiated splenocytes that served as antigen-presenting cells (APC) for the indicated duration. In experiments using inhibitors, cells were pre-incubated in the presence or absence of the inhibitors in complete RPMI containing calcium for 30 min at 37°C. The vehicle control was PBS or DMSO that was diluted to the same concentration. The concentration of DMSO did not exceed 0.1%. Purified CD4\(^+\) T cells obtained from a single Gimap5 mutant rat or mouse are not sufficient to carry out analyses of signaling pathways. Therefore, lymph nodes were pooled from two Gimap5\(^{ob/ob}\) mice for every Gimap5\(^{+/+}\) mouse and from three Gimap5\(^{ob/ob}\) rats for every control rat in any given experiment. Pooled samples were prepared for every repeat experiment. In all experiments, mice and rats were used at 4 weeks of age. Animals were sex-matched within a given experiment, even though both males and females were used.

PP2A activity assay
The PP2A protein phosphatase activity of CD4\(^+\) T cellular lysates was determined by measuring the generation of free phosphate from the threonine phospho-peptide using PP2A immunoprecipitation phosphatase assay kit. Cell lysates were prepared in lysis buffer (20 mM imidazole–HCL, 2 mM EDTA, 2 mM EGTA, PH7.0 with protease inhibitor cocktail). Five hundred micrograms of total cell lysate was immunoprecipitated with anti-PP2A antibody. PP2A activity in the immunoprecipitates was determined using 750 \(\mu\)M phospho-peptide as substrate. After 10 minutes of incubation at 30°C malachite dye was added, and free phosphate was measured by the relative absorbance at 650 nM.
Measurement of Oxygen consumption rates (OCR)

CD4⁺ T cells were stimulated overnight with plate-bound anti-CD3/CD28 and oxygen consumption rate (OCR) (in pmol/min) was measured using Seahorse XF–96 metabolic extracellular flux analyzer (Seahorse Bioscience). Briefly, CD4⁺ T cells were re-suspended in XF assay buffer and were plated onto Seahorse cell plates (6 × 10⁵ cells per well). T cell attachment was enhanced by centrifugation. Cells were incubated at 37°C in a CO₂-free incubator for one hour prior to measurements. Then OCR was measured under basal conditions and following addition of oligomycin (1 μM), FCCP (1.5 μM) and rotenone (100 nM) + antimycin A (1 μM).

ATP assay

The cellular levels of ATP were measured using a bioluminescence assay kit according to the manufacturer’s instructions. Briefly, rat CD4⁺ T cells were untreated or stimulated with antibodies to CD3 and CD28 for the indicated times. The cells were collected and lysed in lysis buffer. The lysates were centrifuged at 13,000×g for 15 min at 4°C and supernatants were collected. ATP concentration was measured in 0.5 μg protein lysate. The luminescence was measured in a Luminometer by the absorbance at 560nM.

SDS-PAGE and Western blot

Cells were washed with cold PBS, harvested and re-suspended in SDS-PAGE sample buffer (50 mM Tris pH 6.8, 1% (w/v) SDS, 1 mM EDTA, 1 mM dithiothreitol). Equivalent amounts of proteins were separated in SDS-PAGE gels and transferred to polyvinylidene difluoride membranes. The blots were probed with primary antibodies followed by incubation with the appropriate HRP-conjugated secondary antibodies and developed with ECL reagent. After incubating in stripping solution (2% SDS, 62.5 mM Tris pH 6.8, 100 mM 2-mercaptoethanol) for 30 min at 55°C, the blots were blocked and re-probed for total proteins.

Statistical analysis

Data were analyzed using two-way ANOVA for statistical comparisons. p values less than 0.05 were considered statistically significant.

Results

Gimap5-deficient T cells show constitutive mTORC1 activity

Despite the inability of CD4⁺ T cells from mice and rats with mutations in the Gimap5 gene to undergo robust proliferation in response to cognate antigens, as well as polyclonal stimulations such as cross-linking CD3 and CD28 or a combination of PMA and ionomycin, these cells were capable of differentiating into Th17 cells [31,36]. As differentiation into Th17 cells is associated with the activation of the mTORC1 complex [32–34], we assessed the mTORC1 pathway by analyzing the phosphorylation of its canonical substrates. Phosphorylation of 4EBP1 releases eIF4E to initiate cap-dependent translation [37]. Phosphorylation of S6K activates its kinase activity that results in the phosphorylation of ribosomal protein S6, a component of the 40S ribosome, which is one of the most characterized substrates of S6K [38]. Following cross-linking CD3/CD28 on the surface of CD4⁺ T cells, phosphorylation of the S6 peaked between 2 and 10 minutes in controls (Fig 1A). To our surprise, we observed that even in the absence of any stimulation, S6 and 4EBP1 were heavily phosphorylated in CD4⁺ T cells from Gimap5<sup>sph/sph</sup> mice (Fig 1A). It is possible that the polyclonality and plasticity of the T cell repertoire could have skewed the distribution of the T cell subsets that are present in the peripheral pool of Gimap5<sup>sph/sph</sup> mice. Therefore, we assessed the expression of pS6 and p4EBP1 in CD4⁺ T cells
from OTII transgenic control and Gimap5sph/sph mice (OTII cells) following stimulation with OVA323-339 presented by irradiated APCs. OTII cells from control mice showed a gradual increase in pS6 protein over a period of 3 hours. However, similar to polyclonal T cells, OTII cells from Gimap5sph/sph mice showed elevated basal levels of expression of pS6 with minimal increase over time (Fig 1B). The increased phosphorylation of S6 was not unique to Gimap5sph/sph mice as loss of functional GIMAP5 resulted in increased phosphorylation of S6 and 4EBP1 in Gimap5lyp/lyp rats as well (Fig 1C). Thirty minutes after stimulation with anti-CD3/CD28, the band corresponding to pS6 was reduced in both control and Gimap5sph/sph T cells (Fig 1A).

These observations suggest that, even if pS6 is constitutively activated, pathways leading to TCR-induced de-phosphorylation of pS6 are not affected by Gimap5 deficiency. As phosphorylation of 4EBP1 and S6 is mediated by signals from mTORC1, we addressed the role of mTORC1 in this phosphorylation. To this end, purified CD4+ T cells from control and Gimap5sph/sph mice were pre-treated with rapamycin, an inhibitor of mTORC1 activity. Pre-treatment with rapamycin inhibited the constitutive and TCR-induced phosphorylation of S6 and 4EBP1 in CD4+ T cells from control and Gimap5sph/sph mice (Fig 1D and 1E). Similarly, the constitutive phosphorylation of S6 and 4EBP4 observed in T cells from Gimap5lyp/lyp rats was also diminished by treatment with rapamycin (Fig 1F), indicating that the increased mTORC1 activity observed in CD4+ T cells, as a consequence of the loss of GIMAP5 functions, is comparable across species.

Activation of AMPK is not altered by Gimap5 mutation

T cell quiescence also requires the suppression of the mTORC1 complex by signals from the LKB1/AMPK pathway [20]. In quiescent T cells catabolic LKB1/AMPK pathway promotes mitochondrial oxidative phosphorylation (OXPHOS) and autophagy to meet the energy requirements. Cytosolic Ca^{2+} influx that follows TCR cross-linking can also transiently activate AMPK to increase the ATP production in anticipation of cell growth [39]. Therefore, we assessed the AMPK status in T cells at rest and following Ca^{2+} influx from intracellular stores. We have shown previously that Ca^{2+} release from the endoplasmic reticulum (ER), following TCR cross-linking, was not affected in T cells from Gimap5lyp/lyp rats [29]. To mimic the TCR-induced Ca^{2+} release from the ER we used thapsigargin (TG), a pharmacological inhibitor of the sarco/endoplasmic reticulum Ca^{2+}-ATPase (SERCA) pump that is involved in the re-filling of the ER Ca^{2+} stores. As the analysis of AMPK signaling was not consistent after stimulation through CD3/CD28, we used TG to induce Ca^{2+} influx. As shown in Fig 2 we did not observe any difference between T cells from control and Gimap5 deficient rats or mice in the basal or Ca^{2+}-induced phosphorylation of AMPK following the addition of TG. Furthermore, the pattern of phosphorylation of ACC, the downstream substrate of AMPK was also comparable between the control and Gimap5 mutants in both the rats and in mice. These results suggest that Gimap5 does not influence the activation of the AMPK pathway in T cells.

Energy requirements of quiescent cells are mostly met from catabolic processes involving mitochondrial oxidative respiration [40]. As Gimap5 mutation results in the loss of
mitochondrial membrane potential over time and reduced ability of mitochondria to buffer cytosolic Ca\textsuperscript{2+} [30], we assessed whether CD4\textsuperscript{+} T cells from Gimap5\textsuperscript{sph/sph} mice showed alterations in OXPHOS. We assessed mitochondrial respiration using an extracellular flux analyzer. Here, alterations in OXPHOS are reflected in the amount of oxygen consumed by the mitochondria, expressed as oxygen consumption rate (OCR). Again, we did not observe any difference in the OCR between T cells from control and Gimap5\textsuperscript{sph/sph} mice (Fig 3A). Similarly, mutation in Gimap5 did not affect the energy production in resting T cells or following cross-linking of CD3/CD28 as measured by the total ATP content in these cells (Fig 3B). Taken together, these observations suggest that Gimap5 does not directly influence the energy content in T cells.

PP2A phosphatase activity is not altered in Gimap5-deficient T cells

The constitutive phosphorylation of S6 and 4EBP1 in T cells from Gimap5 mutant mice and rats could also arise from suboptimal phosphatase activity. PP2A, a serine/threonine protein phosphatase, is the major phosphatase responsible for the de-phosphorylation of S6 and 4EBP1 [41]. An earlier study had shown that apoptosis induced by okadaic acid (OA), an inhibitor of the PP2A could be prevented by transfection with human GIMAP5 (previously called IAN5) gene [42]. As a corollary, we have also observed that Gimap5\textsuperscript{lyp/lyp} T cells lacking functional Gimap5 showed increased sensitivity to OA-induced apoptosis (S1 Fig). We confirmed the role of PP2A in dephosphorylating S6 and 4EBP1 by treating the cells with calyculin A, an inhibitor of PP2A [43]. As expected, treatment with calyculin A resulted in an increased phosphorylation of S6 and 4EBP1 and AKT (S2 Fig). To determine whether the constitutive phosphorylation of S6 and 4EBP1 could be the result of decreased PP2A activity, we measured the activity of PP2A in the lysates of CD4\textsuperscript{+} T cells from Gimap5\textsuperscript{lyp/lyp} rats. Under steady state conditions, the activity of PP2A was comparable in CD4\textsuperscript{+} T cells from Gimap5 deficient and control rats (Fig 4). These observations suggest that the persistence of the phosphorylation of S6 and 4EBP1 cannot be attributed to decreased phosphatase activity, per se.

Gimap5 deficiency results in constitutively active AKT

Cross-linking of TCR/CD3 complex results in the recruitment of PI3K to the CD3 complex, to generate phosphatidylinositol (3,4,5)-triphosphate (PIP3) at the plasma membrane [44].
Phosphoinositide-dependent kinase–1 (PDK1) and AKT are recruited by PIP3 through their pleckstrin homology (PH) domains leading to the phosphorylation of AKT at Thr308, followed by the phosphorylation of Ser473 by the mTORC2 complex [45]. Activated AKT phosphorylates the TSC1/TSC2 complex, resulting in the inhibition of its GAP activity and releasing the RHEB GTPase to activate mTORC1 [46]. We assessed whether the increased phosphorylation of AKT following cross-linking of TCR/CD3 complex and CD28 could explain the increased mTOR activity. In CD4+ T cells from control mice, we observed that the pAKT peaked between 2 and 10 minutes after CD3/CD28 cross-linking, and returned to the basal level by 30 minutes (Fig 5A). In contrast, phosphorylation of AKT was detected even in the absence of stimulation in CD4+ T cells from Gimap5sph/sph mice (Fig 5A). Crosslinking CD3/CD28 also increased the pAKT that returned to basal level within 30 minutes in Gimap5sph/sph CD4+ T cells. But it was still higher than that observed in the control cells.
Following activation of control OTII cells with peptide/APC, phosphorylation of AKT was evident at 5 minutes and was strong even at 180 minutes (Fig 5B). However, in Gimap5 mutant OTII cells, pAKT was detected even in the absence of stimulation and showed minimal increase over time (Fig 5B). Increased basal AKT phosphorylation was also observed in CD4+ T cells from Gimap5sph/sph mice (Fig 5C). These results strongly indicated that loss of functional GIMAP5 protein results in elevated basal phosphorylation of AKT in T cells. A previous report has shown that the expression of FOXO1, the down stream target of AKT, is reduced in CD4+ T cells from 4-week old Gimap5sph/sph mice [31]. We observed that the phosphorylation of FOXO1 is comparable or lower in Gimap5 mutant CD4+ T cells even in the presence of hyper-activated Akt (Figs 5 and 6). Furthermore, to confirm that the activation of AKT was not an artifact, we determined the phosphorylation status of AKT and FOXO1 in the cells where mTOR was inhibited. While phosphorylation downstream of mTORC1 was inhibited following pre-treatment with rapamycin (Fig 1D, 1E and 1F), phosphorylation of AKT and FOXO1 remained unchanged (Fig 5D and 5E). These results indicate that the constitutive activation of AKT likely underlies the activation of the mTORC1 pathway in T cells lacking functional GIMAP5 protein.

Constitutively activated PI3K is responsible for the increased pAKT in GIMAP5 deficient T cells

Engagement of the TCR or IL-7R activates PI3K to generate PIP3 at the plasma membrane which results in the recruitment and activation of AKT [47]. To determine whether the phosphorylation of AKT was secondary to the activated state of PI3K, we pretreated the cells with different inhibitors of PI3K. LY294002 (LY) and CAL–101 markedly diminished the intensity of the pAKT in CD4+ T cells from control and Gimap5sph/sph mice and Gimap5sph/sph rats (Fig 6 and S3 Fig). Phosphorylation of AKT following activation of OTII cells with ova peptide was also completely prevented by CAL–101 (Fig 6D). More importantly, inhibition of PI3K greatly
diminished the amount of constitutive pAKT, indicating that aberrant activation of PI3K may be the underlying cause for the activation of the AKT/mTOR pathway. In addition, the level of pFOXO1, an mTORC1-independent substrate of pAKT was also reduced following treatment with PI3K inhibitors (Fig 6). The pattern of inhibition between LY and CAL–101 was comparable in control and mutant cells (Fig 6A versus 6C and Fig 6B versus 6D). While LY is pan PI3K inhibitor, CAL–101 is specific to PI3Kdelta isoform that is active in lymphocytes [44]. Thus, it is reasonable to conclude that the constitutive phosphorylation of AKT is essentially mediated by PI3K delta in the T cells from Gimap5 mutant mice.

Discussion

Long-term survival of T lymphocytes in a quiescent state is essential to maintain their cell numbers in the peripheral circulation and in secondary lymphoid organs. Even though cytokines, T cell antigen receptor and various signaling pathways are implicated in the maintenance of T cell survival, the processes by which these signaling pathways are integrated are not yet well understood. In BB-DP rats, T lymphopenia, that arises due to the recessive mutation in the lyp allele, promotes abortive homeostatic expansion of T cells resulting in autoimmune diabetes [6] (reviewed in [7]). As a consequence of this mutation, single positive thymocytes and mature T lymphocytes undergo spontaneous apoptosis [48,49]. Twenty years after its discovery, the mutation was mapped to the Gimap5 locus (formerly Ian5) leading to the discovery of a new family of proteins [3,4]. A GTPase domain in the N-terminus that can potentially hydrolyze GTP characterizes GIMAP proteins. Some of these possess a C-terminal hydrophobic trans-membrane domain, which targets GIMAP5 to the endo-lysosomal compartment [50]. While in rats the functional consequence of Gimap5 mutation is restricted to the T cell lineage, in mice it extends to other hematopoietic cells and prevents the survival of hematopoietic stem cells [8,9].

In Gimap5<sup>lyp/lyp</sup> rats the frame-shift mutation truncates the coding sequence at amino acid 109 such that the putative polypeptide product lacks both a functional GTPase domain and the C-terminal membrane anchor. [3,4]. In Gimap5<sup>sph/sph</sup> mice a point mutation disrupts the functional GTPase domain. While the mRNA is expressed, the protein is not detected, probably due to its lack of stability [9]. These observations suggest that the GTPase domain of GIMAP5 protein may be functional. Studies with GIMAP2 indicate that the GTPase domain in GIMAP2, 7 and 5 can bind GTP and can potentially hydrolyze GTP when they form dimers [51]. GIMAP5 has comparable functions, at least in T cells, in both rats and mice as observed in this study where we have carried out most of the experiments in both Gimap5 mutant rats and mice.

Most of the GIMAP proteins are expressed in the cells of the hematopoietic system [52]. However, the mechanisms by which GIMAP proteins promote the survival of T and B lymphocytes are far from well understood. In mice, GIMAP5 has been reported to interact with the members of the Bcl–2 family [2,10]. However, we did not observe co-localization of Bcl–2 with rat GIMAP5 in primary rat T lymphocytes or following overexpression [35]. Our observations rather suggest that GIMAP5 may be involved in the integration of the survival signals generated through the TCR by regulating the calcium homeostasis in T lymphocytes [29]. In fact the
Spontaneous AKT Activation in Gimap5-Deficient T Cells

**A**

\( \alpha \text{CD3/CD28} \)

| \( \text{Gimap5}^{+/+} \) +LY | \( \text{Gimap5}^{sph/sph} \) +LY |
|---|---|
|  \( \text{pAkt(S473)} \) |  \( \text{Akt} \) |
|  \( \text{pFOXO1} \) |  \( \text{FOXO1} \) |
|  \( \text{Actin} \) |

\( \text{Gimap5}^{+/+} \)  \( \text{Gimap5}^{sph/sph} \)

**B**

| Peptide+APC |
|---|
| OTII | OTII^{sph/sph} |
| +LY | +LY |

\( \text{pAkt(S473)} \)  \( \text{Akt} \)  \( \text{pFOXO1} \)  \( \text{FOXO1} \)  \( \text{pS6} \)  \( \text{S6} \)  \( \text{Actin} \)

| 0 | 120 | 180 | 0 | 120 | 180 | (min) |

**C**

\( \alpha \text{CD3/CD28} \)

| \( \text{Gimap5}^{+/+} \) +CAL-101 | \( \text{Gimap5}^{sph/sph} \) +CAL-101 |
|---|---|
|  \( \text{pAkt(S473)} \) |  \( \text{Akt} \) |
|  \( \text{pFOXO1} \) |  \( \text{FOXO1} \) |
|  \( \text{Actin} \) |

\( \text{Gimap5}^{+/+} \)  \( \text{Gimap5}^{sph/sph} \)

**D**

| Peptide+APC |
|---|
| OTII | OTII^{sph/sph} |
| +CAL-101 | +CAL-101 |

\( \text{pAkt(S473)} \)  \( \text{Akt} \)  \( \text{pFOXO1} \)  \( \text{FOXO1} \)  \( \text{Actin} \)

| 0 | 120 | 180 | 0 | 120 | 180 | (min) |
TCR-induced release of Ca\textsuperscript{2+} from the ER stores is normal in GIMAP5 deficient T cells suggesting that certain aspects of the proximal TCR signaling machinery is intact in these cells [29]. The reduced Ca\textsuperscript{2+} influx may possibly be attributable to the inability of the mitochondria to move on microtubules to buffer the cytosolic Ca\textsuperscript{2+} in the absence of functional GIMAP5 protein [30]. A similar function has been recently reported for GIMAP4 that interacts with actin and tubulin for cytokine secretion in CD4\textsuperscript{+} T cells [53]. These observations collectively raise the possibility that the survival defect in these Gimap5 mutant T cells can also, in part, be due to defects in vesicular traffic.

Despite the lymphopenia and the defective proliferative response following TCR stimulation, Gimap5-deficient T cells do differentiate into Th17 cells and contribute to tissue pathologies [9,36,54]. T cell-specific deletion of regulatory associated protein of mTOR (RAPTOR), the mTOR binding partner that also binds p70S6k and 4E-BP1, prevents the down-regulation of Gfi1, a negative regulator of Th17 differentiation [55]. Our observations show that this skewing towards Th17 differentiation in Gimap5-deficient T can be attributed to the increased mTORC1 signaling (Fig 1). As a consequence, Gimap5-deficient T cells show a decrease in the Treg population, which could also aggravate the observed pathologies [9,56]. However, it is not clear if the observed phenotypes are secondary to lymphopenia. Competitive reconstitution leads to the loss of the mutant T cells over time in rats, making it difficult to address the role of lymphopenia [49]. However, reconstitution with Gimap5-sufficient cells greatly reduced the development of autoimmune diabetes in the rat model and the intestinal lesions in the mouse model [7,9], suggesting that the manifestation of the pathologies associated with the Gimap5 mutation are secondary to the lymphopenia-induced activation.

Quiescence in T cells also requires the repression of mTORC1 pathway by the LKB1/AMPK axis that promotes catabolic pathways involving mitochondrial OXPHOS [20]. The activation of the mTORC1 pathway is not due to defects in AMPK activation as seen from the equivalent activation of AMPK and the mitochondrial OXPHOS in Gimap5 deficient T cells (Figs 2 and 3). Rather, Gimap5-deficient T cells show spontaneous activation of AKT, which then activates the mTORC1 pathway through the suppression of the TSC complex (Fig 5). The constitutive activation of AKT appears to be specific to T lymphocytes as it is not observed in B cells, even though their survival is also affected in the absence of GIMAP5 [9]. Thus, activation of the mTORC1 pathway can be attributed to the spontaneous activation of the PI3K/AKT axis.

T cells require two signals to sustain T cell activation, cytokine production and cell proliferation [57]. The primary signal through the TCR needs to be accompanied by a second signal through the co-stimulatory molecules. Signals through the TCR complex alone, in the absence of co-stimulation, result in the development of anergic T cells that cannot easily respond to robust re-stimulation through the TCR [58]. Recently, two groups have reported that spontaneous gain of function mutations in PI3K resulted in profound immunodeficiency, as these T cells were unable to mount an efficient immune response to cross-linked anti-CD3/CD28 stimulation [59,60]. Similarly, here we show that as a consequence of the mutation in Gimap5, the PI3K/AKT axis is constitutively activated in the absence of spontaneous activation of TCR-mediated proximal signaling pathways. It has been shown that mutations in PI3K can alter the signaling threshold during T cell development [61]. However analysis of the phenotype of thymocytes in Gimap5 mutant rats and mice suggest that GIMAP5 is required for T cell survival.
during later stages of T cell development in the thymus and in the periphery. We hope that the dissection of the signaling pathways in GIMAP5-deficient cells will eventually contribute to the understanding of the mechanisms through which GIMAP5 promotes the survival of lymphocytes.

Supporting Information

S1 Fig. Gimap5 bp/bp T cells are more sensitive to OA induced apoptosis. Total lymphocytes from control and Gimap5bp/bp rat were cultured with or without 200 nm OA for 8 h. The apoptosis in gated CD4+ lymphocytes was analyzed by annexin V staining using flow cytometry. The number of cells recovered from cultures of lymphocytes Gimap5bp/bp rats diminishes with time. As a consequence only few CD4+ cells can be acquired in the live gate. Representative data from 3 independent experiments are shown.

(TIF)

S2 Fig. PP2A inhibitor markedly increased the basal level of phosphorylation of PP2A substrates. CD4+ T cells from wild type mice were treated with PP2A specific inhibitor calyculin A for 1 h. The phosphorylation of S6, 4EBP1 and AKT was analyzed by Western blotting. Representative data from 2 independent experiments are shown.

(TIF)

S3 Fig. Inhibition of PI3K diminished the phosphorylation of AKT in both control and Gimap5 deficient CD4+ T cells. CD4+ T cells from control and Gimap5bp/bp rats were treated with 1 μM CAL-101 for 30 min followed by TCR stimulation. The lysates were analyzed with indicated antibodies. Representative data from 3 independent experiments are shown.

(TIF)

Author Contributions

Conceived and designed the experiments: SR XLC. Performed the experiments: XLC MM DS. Analyzed the data: SR XLC. Contributed reagents/materials/analysis tools: SI KH. Wrote the paper: SR XLC.

References

1. Dion C, Carter C, Hepburn L, Coadwell WJ, Morgan G, Graham M, et al. Expression of the Ian family of putative GTPases during T cell development and description of an Ian with three sets of GTP/GDP-binding motifs. Int Immunol. 2005; 17(9):1257–68. Epub 2005/08/17. doi: dxh302 [pii] doi:10.1093/intimm/dxh302 PMID: 16103028.

2. Nitta T, Nasreen M, Seike T, Goji A, Ohigashi I, Miyazaki T, et al. IAN family critically regulates survival and development of T lymphocytes. PLoS Biol. 2006; 4(4):e103. Epub 2006/03/03. doi: 05-PLBI-RA-0742R3 [pii] doi: 10.1371/journal.pbio.0040103 PMID: 16509771; PubMed Central PMCID: PMC1393758.

3. Hornum L, Romer J, Markholst H. The diabetes-prone BB rat carries a frameshift mutation in Ian4, a positional candidate of Iddm1. Diabetes. 2002; 51(6):1972–9. Epub 2002/05/29. PMID: 12031988.

4. MacMurray AJ, Moralejo DH, Kwiatak AE, Rutledge EA, Van Yserloo B, Gohlke P, et al. Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. Genome Res. 2002; 12(7):1029–39. Epub 2002/07/05. doi: 10.1101/gr.412702 PMID: 12097358; PubMed Central PMCID: PMC186618.

5. Jackson R, Rassi N, Crump T, Haynes B, Eisenbarth GS. The BB diabetic rat. Profound T-cell lymphopenia. Diabetes. 1981; 30(10):887–9. Epub 1981/10/01. PMID: 6974111.

6. Poussier P, Nakhooda AF, Falk JA, Lee C, Marliss EB. Lymphopenia and abnormal lymphocyte subsets in the "BB" rat: relationship to the diabetic syndrome. Endocrinology. 1982; 110(5):1825–7. Epub 1982/05/01. doi: 10.1210/endo-110-5-1825 PMID: 6978807.
7. Ramanathan S, Poussier P. BB rat lyp mutation and Type 1 diabetes. Immunol Rev. 2001; 184:161–71. Epub 2002/06/28. PMID: 12086310.

8. Schultz D, Chu H, Dai X, Chen Y, Edwards B, Haribhai D, et al. Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking Gimap5. Blood. 2008; 112(13):4905–14. Epub 2008/09/18. doi:10.1182/blood-2008-03-146555 [pii].

9. Barnes MJ, Aksoylar H, Krebs P, Bourdeau T, Arnold CN, Xia Y, et al. Loss of T cell and B cell quiescence precedes the onset of microbial flora-dependent wasting disease and intestinal inflammation in Gimap5-deficient mice. J Immunol. 2010; 184(7):3743–54. Epub 2010/03/02. doi: jimmunol.0903164 [pii].

10. Chen Y, Yu M, Dai X, Zogg M, Wen R, Weiler H, et al. Critical role for Gimap5 in the survival of mouse hematopoietic stem and progenitor cells. J Exp Med. 2011; 208(5):923–35. Epub 2011/04/20. doi: 10.1084/jem.201101192 [pii].

11. Maraskovsky E, Teepe M, Morrissey PJ, Braddy S, Miller RE, Lynch DH, et al. Impaired survival and proliferation in IL-7 receptor-deficient peripheral T cells. J Immunol. 1996; 157(12):5315–23. Epub 1996/12/15. PMID: 8955178.

12. Takeda S, Rodewald HR, Arakawa H, Bluethmann H, Shimizu T. MHC class II molecules are not required for survival of newly generated CD4+ T cells, but affect their long-term life span. Immunity. 1996; 5(3):217–28. PMID: 880677.

13. Revy P, Sospedra M, Barbour B, Trautmann A. Functional antigen-independent synapses formed between T cells and dendritic cells. Nat Immunol. 2001; 2(10):925–31. PMID: 11561183.

14. Seddon B, Tomlinson P, Zamozyska R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol. 2003; 4(7):680–6. PMID: 12808452.

15. Wei SH, Sairina O, Yu Y, Garrod KR, Cahalan MD, Parker I. Ca2+ signals in CD4+ T cells during early interactions with antigen-bearing dendritic cells in lymph node. J Immunol. 2007; 179(3):1586–94. PMID: 17641025.

16. Mazzucchelli R, Durum SK. Interleukin–7 receptor expression: intelligent design. Nat Rev Immunol. 2007; 7(2):144–54. Epub 2007/01/30. doi: nri2023 [pii].

17. Kuo CT, Veselits ML, Leiden JM. LKLF: A transcriptional regulator of single-positive T cell quiescence and survival. Science. 1997; 277(5334):1986–90. PMID: 9302292.

18. Maclver NJ, Biaglini J, Saucillo DC, Tonelli L, Griss T, Rathmell JC, et al. The liver kinase B1 is a central regulator of T cell development, activation, and metabolism. J Immunol. 2011; 187(8):4187–98. Epub 2011/09/21. doi: jimmunol.1100367 [pii].

19. Gerriets VA, Rathmell JC. Metabolic pathways in T cell fate and function. Trends in immunology. 2012; 33(4):168–73. Epub 2012/02/22. doi: jimmunol.1200342 [pii].

20. Biaglini J, Krawczyk CM, Jones RG. LKB1 and AMPK: central regulators of lymphocyte metabolism and function. Immunol Rev. 2012; 249(1):59–71. doi: 10.1111/j.1600-065X.2012.01157.x PMID: 22889215.

21. Yusuf I, Fruman DA. Regulation of quiescence in lymphocytes. Trends in immunology. 2003; 24(7):380–6. Epub 2003/07/16. PMID: 12860529.

22. Zeng H, Chi H. mTOR and lymphocyte metabolism. Current opinion in immunology. 2013; 25(3):347–55. Epub 2013/06/01. doi: jimmunol.1200052 [pii].

23. Wu Q, Liu Y, Chen C, Ikenoue T, Qiao Y, Li CS, et al. The tuberous sclerosis complex-mammalian target of rapamycin pathway maintains the quiescence and survival of naive T cells. J Immunol. 2011; 187(3):1106–12. Epub 2011/06/29. doi: jimmunol.1003968 [pii].

24. Yang K, Neale G, Green DR, He W, Chi H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat Immunol. 2011; 12(9):888–97. Epub 2011/07/19. doi: nri2068 [pii].

25. Powell JD, Polizzii KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annual review of immunology. 2012; 30:39–68. Epub 2011/12/06. doi: jimmunol.1100094 [pii].

26. Beugnet A, Wang X, Proud CG. Target of rapamycin (TOR)-signaling and RAP1 motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1. The Journal of biological chemistry. 2003; 278(42):40717–22. Epub 2003/08/13. doi: jbc.M308573200 [pii].
27. Tamas P, Macintyre A, Finlay D, Clarke R, Feijooy-Camero C, Ashworth A, et al. LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells. Eur J Immunol. 2010; 40(1):242–53. Epub 2009/10/16. doi:10.1002/eji.200939677 PMID: 19830737; PubMed Central PMCID: PMC2988414.

28. O’Brien TF, Gorentla BK, Xie D, Srivatsan S, McLeod IX, He YW, et al. Regulation of T-cell survival and mitochondrial homeostasis by TSC1. Eur J Immunol. 2011; 41(11):3361–70. Epub 2011/08/02. doi:10.1002/eji.201141411 PMID: 21805467; PubMed Central PMCID: PMC3241742.

29. Ilangumaran S, Forand-Boulerice M, Bousquet SM, Savard A, Rocheleau P, Chen XL, et al. Loss of GIMAP5 (GTPase of immunity-associated nucleotide binding protein 5) impairs calcium signaling in rat T lymphocytes. Molecular immunology. 2009; 46(6):1256–9. PMID:19007993. doi:10.1016/j.molimm.2008.09.031

30. Chen XL, Serrano D, Mayhue M, Wieden HJ, Stankova J, Boulay G, et al. GTPase of the immune-associated nucleotide-binding protein 5 (GIMAP5) regulates calcium influx in T-lymphocytes by promoting mitochondrial calcium accumulation. The Biochemical journal. 2013; 449(2):353–64. doi:10.1042/BJ20120516 PMID: 23098229.

31. Aksoylar HI, Lampe K, Barnes MJ, Plas DR, Hoebe K. Loss of immunological tolerance in Gimap5-deficient mice is associated with loss of Foxo in CD4+ T cells. J Immunol. 2012; 188(1):146–54. Epub 2011/11/23. doi: jimmunol.1101206 [pii] doi:10.4049/jimmunol.1101206 PMID: 22106000; PubMed Central PMCID: PMC3258489.

32. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity. 2009; 30(6):832–44. Epub 2009/06/23. doi:10.1016/j.immuni.2009.04.014 PMID: 19538929; PubMed Central PMCID: PMC2768135.

33. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. 2011; 12(4):295–303. Epub 2011/03/02. doi: 10.1038/ni.2005 PMID: 21358638; PubMed Central PMCID: PMC3077821.

34. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood. 2013; 121(13):2402–14. Epub 2013/01/18. doi:10.1182/blood-2012-09-378653 PMID: 23325835; PubMed Central PMCID: PMC3612853.

35. Keita M, Leblanc C, Andrews D, Ramanathan S. GIMAP5 regulates mitochondrial integrity from a distinct subcellular compartment. Biochemical and biophysical research communications. 2007; 361(2):481–6. PMID:17655828.

36. van den Brandt J, Fischer HJ, Walter L, Hunig T, Kloting I, Reichardt HM. Type 1 diabetes in BioBreeding rats is critically linked to an imbalance between Th17 and regulatory T cells and an altered TCR repertoire. J Immunol. 2010; 185(4):2285–94. doi:10.4049/jimmunol.1000462 PMID: 20644174.

37. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 1996; 15(3):658–64. PMID: 8599949; PubMed Central PMCID: PMC4499984.

38. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70-kDa S6 protein kinases. Cell. 1992; 69(7):1227–36. PMID: 1377606.

39. Tamas P, Hawley SA, Clarke RG, Mustard KJ, Green K, Hardie DG, et al. Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca2+ in T lymphocytes. J Exp Med. 2006; 203(7):1665–70. Epub 2006/07/05. doi:10.1084/jem.20052469 PMID: 16818670; PubMed Central PMCID: PMC2118355.

40. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007; 8(10):774–85. doi:10.1038/nrm2249 PMID: 17712357.

41. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 2005; 15(1):34–41. Epub 2005/01/22. doi: S0959-437X(04)00190-X [pii] doi:10.1016/j.gde.2004.12.004 PMID: 15661531.

42. Sandal T, Aumo L, Hedin L, Gjertsen BT, Doskeland SO. Irod/Ian5: an inhibitor of gamma-radiation-and okadaic acid-induced apoptosis. Molecular biology of the cell. 2003; 14(8):3292–304. PMID: 12925764.

43. Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U S A. 1999; 96(8):4438–42. Epub 1999/04/14. PMID: 10200280; PubMed Central PMCID: PMC16350.

44. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annual review of immunology. 2013; 31:675–704. doi: 10.1146/annurev-immunol-032712-095946 PMID: 23330955.
45. Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Current topics in microbiology and immunology. 2010; 346:31–56. doi: 10.1007/82_2010_58 PMID: 20517722.

46. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005; 121(2):179–93. Epub 2005/04/27. doi: S0092-8674(05)00198-4 [pii] doi:10.1016/j.cell.2005.02.031 PMID: 15851026.

47. Anderson KE, Coadwell J, Stephens LR, Hawkins PT. Translocation of PDK1 to the plasma membrane is important in allowing PDK1 to activate protein kinase B. Current biology: CB. 1998; 8(12):684–91. Epub 1998/06/25. PMID: 9637919.

48. Hernandez-Hoyos G, Joseph S, Miller NG, Butcher GW. The lymphopenia mutation of the BB rat causes inappropriate apoptosis of mature thymocytes. Eur J Immunol. 1999; 29(6):1832–41. PMID: 10382745.

49. Lau A, Ramanathan S, Poussier P. Excessive production of nitric oxide by macrophages from DP-BB rats is secondary to the lymphopenic state of these animals. Diabetes. 1998; 47(2):197–205. PMID: 9519713.

50. Wong VW, Saunders AE, Hutchings A, Pascall JC, Carter C, Bright NA, et al. The autoimmunity-related GMAP5 GTPase is a lysosome-associated protein. Self Nonself. 2010; 1(3):259–68. doi: 10.4161/self.1.3.12819 PMID:21487483; PubMed Central PMCID: PMC3047789.

51. Schwefel D, Arasu BS, Marino SF, Lamprecht B, Kochert K, Rosenbaum E, et al. Structural insights into the mechanism of GTPase activation in the GMAP family. Structure. 2013; 21(4):550–9. doi: 10.1016/j.str.2013.01.014 PMID: 23454188.

52. Filen S, Lahesmaa R. GMAP Proteins in T-Lymphocytes. Journal of signal transduction. 2010; 2010:268589. doi: 10.1155/2010/268589 PMID:21637352; PubMed Central PMCID: PMC3100574.

53. Heinonen MT, Kanduri K, Lahdesmaki HJ, Lahesmaa R, Henttinien TA. Tubulin- and actin-associating GIMAP4 is required for IFN-gamma secretion during Th cell differentiation. Immunology and cell biology. 2014. doi:10.1038/icb.2014.86 PMID: 25287446.

54. Hillebrands JL, Rozing J, Visser JT. Comment on "Type 1 diabetes in BioBreeding rats is critically linked to an imbalance between Th17 and regulatory T cells and an altered TCR repertoire". J Immunol. 2011; 186(3):1297–8; author reply 8–9. doi: 10.4049/jimmunol.1090132 PMID: 21248265.

55. Kurebayashi Y, Nagai S, Ikejiri A, Ohtani M, Ichiyama K, Baba Y, et al. PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfr1 expression and nuclear translocation of RORgamma. Cell Rep. 2012; 1(4):360–73. Epub 2012/07/27. doi: S2211-1247(12)00064-2 [pii] doi:10.1016/j.celrep.2012.02.007 PMID: 22832227.

56. Poussier P, Ning T, Murphy T, Dabrowski D, Ramanathan S. Impaired post-thymic development of regulatory CD4+25+ T cells contributes to diabetes pathogenesis in BB rats. J Immunol. 2005; 174(7):4081–9. PMID: 15778366.

57. Malissen B, Greigre C, Malissen M, Roncagalli R. Integrative biology of T cell activation. Nat Immunol. 2014; 15(9):790–7. Epub 2014/08/20. doi: 10.1038/ni.2959 PMID: 25137453.

58. Chappert P, Schwartz RH. Induction of T cell anergy: integration of environmental cues and infectious tolerance. Current opinion in immunology. 2010; 22(5):552–9. doi: 10.1016/j.coi.2010.08.005 PMID: 20869863; PubMed Central PMCID: PMC2981408.

59. Angulo I, Vadas O, Garcon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science. 2013; 342(6160):866–71. doi: 10.1126/science.1243292 PMID: 24136356; PubMed Central PMCID: PMC3930011.

60. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germ-line mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol. 2014; 15(1):88–97. doi: 10.1038/ni.2771 PMID: 24165795; PubMed Central PMCID: PMC4209962.

61. Okkenhaug K, Furman DA. PI3Ks in lymphocyte signaling and development. Current topics in microbiology and immunology. 2010; 346:57–85. Epub 2010/06/22. doi:10.1007/82_2010_45 PMID: 20963708.